This article was originally published in Pharmaceutical Approvals Monthly
Actelion's type I Gaucher disease therapy Zavesca (miglustat) is approved July 31 as second-line treatment to Genzyme's Cerezyme (imiglucerase) in adults for whom "enzyme replacement therapy is not an option." The firm estimates the eligible population at 200-300 patients. The product will be available to a limited number of physicians due to neuropathy concerns and pregnancy category X status. Actelion and Celltech are studying miglustat in type III Gaucher disease, Niemann-Pick type C and late onset Tay-Sachs..
You may also be interested in...
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.
New directors at 4D Pharma, Neurogene And Zogenix.